MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Public ClinicalTrials.gov record NCT07505303. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity
Study identification
- NCT ID
- NCT07505303
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eccogene
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- ECC4703 Drug
- Placebo Drug
- Semaglutide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 12, 2026
- Primary completion
- Nov 19, 2026
- Completion
- Nov 19, 2026
- Last update posted
- Mar 31, 2026
2026
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Research Associates - Flourish - PPDS | Birmingham | Alabama | 35205 | — |
| Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS | Anaheim | California | 92081 | — |
| Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS | Los Alamitos | California | 90720 | — |
| AES - DRS - Optimal Research Florida - Melbourne | Melbourne | Florida | 32934 | — |
| ForCare Clinical Research - CenExel FCR - PPDS | Tampa | Florida | 33613 | — |
| Atlanta Center for Medical Research - CenExel ACMR - PPDS | Atlanta | Georgia | 30331 | — |
| iResearch Atlanta - CenExel - PPDS | Decatur | Georgia | 30030 | — |
| AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis | Richfield | Minnesota | 55423 | — |
| Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS | Omaha | Nebraska | 68134 | — |
| Velocity Clinical Research - Durham - PPDS | Durham | North Carolina | 27701 | — |
| Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS | Cincinnati | Ohio | 45246 | — |
| Velocity Clinical Research - Providence - PPDS | East Greenwich | Rhode Island | 02818 | — |
| Velocity Clinical Research - Dallas - PPDS | Dallas | Texas | 75230 | — |
| AES - DRS - Synexus Clinical Research US, Inc. - San Antonio | San Antonio | Texas | 78229 | — |
| Flourish Research - San Antonio - PPDS | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07505303, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07505303 live on ClinicalTrials.gov.